Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/1958
DC FieldValueLanguage
dc.contributor.authorWakim, Rima Hannaen_US
dc.contributor.authorChehab, Hibaen_US
dc.contributor.authorMahfouz, Imaneen_US
dc.contributor.authorNassar, Farahen_US
dc.contributor.authorBaroud, Maysaen_US
dc.contributor.authorShehab, Marwaen_US
dc.contributor.authorPimentel, Guillermoen_US
dc.contributor.authorWasfy, Momtazen_US
dc.contributor.authorHouse, Brenten_US
dc.contributor.authorAraj, Georgesen_US
dc.contributor.authorMatar, Ghassan M.en_US
dc.contributor.authorDbaibo, Ghassanen_US
dc.date.accessioned2020-12-23T09:03:48Z-
dc.date.available2020-12-23T09:03:48Z-
dc.date.issued2012-
dc.identifier.urihttps://scholarhub.balamand.edu.lb/handle/uob/1958-
dc.description.abstractInvasive pneumococcal disease (IPD) associated with Streptococcus pneumonia is a major public health problem worldwide for all age groups, including in Lebanon. Prevention through vaccination remains the most valuable tool to decrease the burden of disease. Pneumococcal conjugate vaccine 7 (PCV7), marketed internationally including in the Middle East and North Africa region for the prevention of IPD, was introduced in Lebanon in 2006, followed by PCV10 and PCV13 in 2010. However, none of these is currently part of the Extended Program of Immunization schedule and published data on IPD incidence, pneumococcal serotypes and vaccine coverage in the region are lacking. The Lebanese Inter-Hospital Pneumococcal Surveillance Program is a surveillance system set up to determine the burden of IPD and the prevalent serotypes responsible. The aim of this prospective 6-year study carried out in 78 hospitals throughout Lebanon was to obtain such data to help health authorities make informed decisions on the implementation of pneumococcal vaccination at the national level. A total of 257 isolates of culture-confirmed Streptococcus pneumoniae were evaluated. Considering all age groups, vaccine coverage was 41.4%, 53.9%, and 67.2% for PCV7, PCV10, and PCV13 serotypes, respectively; for patients <2, 2–5, and >60 years of age, PCV7 coverage was 50%, 51%, and 35%, respectively; PCV10 coverage was 53%, 74%, 45%, respectively; and PCV13 coverage was 63%, 80%, and 68%, respectively. Overall, 17.4% of these isolates were penicillin-G non-susceptible using the latest established breakpoints and mortality occurred in 23.5% of the patients with non-susceptible isolates. In addition, 10.9% of isolates were multi-drug-resistant. The highest mortality rates were observed in the eldest (>60 years of age) and youngest (<2 years of age) patients. The most prevalent invasive serotypes identified were those found in currently available pneumococcal conjugate vaccines, emphasizing the importance of i.en_US
dc.format.extent7 p.en_US
dc.language.isoengen_US
dc.subjectS. pneumoniaeen_US
dc.subjectSerotypeen_US
dc.subjectResistanceen_US
dc.subject.lcshPediatricsen_US
dc.subject.lcshLebanonen_US
dc.subject.lcshMiddle Easten_US
dc.titleEpidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanonen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1016/j.vaccine.2012.07.020-
dc.contributor.affiliationFaculty of Medicineen_US
dc.description.volume30en_US
dc.description.issueS6en_US
dc.description.startpageG11en_US
dc.description.endpageG17en_US
dc.date.catalogued2017-12-19-
dc.description.statusPublisheden_US
dc.identifier.ezproxyURLhttp://ezsecureaccess.balamand.edu.lb/login?url=https://doi.org/10.1016/j.vaccine.2012.07.020en_US
dc.identifier.OlibID175717-
dc.relation.ispartoftextJournal of vaccineen_US
dc.provenance.recordsourceOliben_US
Appears in Collections:Faculty of Medicine
Show simple item record

SCOPUSTM   
Citations

17
checked on Jun 19, 2021

Google ScholarTM

Check

Dimensions Altmetric

Dimensions Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.